MRUS Overview
Upcoming Projects (MRUS)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MRUS)
-
A look at the potential of Merus’ Petosemtamab (MCLA-158) and the Phase 2 data presented at ASCO in HNSCC.
Ticker: MRUS
Executed On: Jun 06, 2024 at 09:30 AM EDT -
A Third Look: Discussing the 2023 AACR presentation of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma (HNSCC)
Ticker: MRUS
Executed On: Feb 15, 2024 at 10:00 AM EST -
A Second Look: Discussing the 2023 AACR presentation of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma (HNSCC)
Ticker: MRUS
Executed On: Jan 29, 2024 at 12:00 PM EST -
Discussing the 2023 AACR presentation of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma (HNSCC)
Ticker: MRUS
Executed On: Jan 24, 2024 at 03:30 PM EST -
A Second Look: Examining the potential of Merus' bispecific antibody, petosemtamab, in HNSCC with a focus on the data from the Phase 1/2 trial presented AACR 2023
Ticker: MRUS
Executed On: Apr 27, 2023 at 09:00 AM EDT -
Examining the potential of Merus' bispecific antibody, petosemtamab, in HNSCC with a focus on the data from the Phase 1/2 trial presented AACR 2023
Ticker: MRUS
Executed On: Apr 26, 2023 at 09:45 AM EDT -
Discussing the potential of Petosemtamab in treating Head and Neck Cancer (HNSCC) and how it compares to other EGFR biologics
Ticker: MRUS
Executed On: Jul 28, 2022 at 04:00 PM EDT -
Discussing Merus' MCLA-158 in advanced head and neck squamous cell carcinoma with an author of the 2021 AACR-NCI-EORTC presentation
Ticker: MRUS
Executed On: Apr 07, 2022 at 04:00 PM EDT
Expired Projects (MRUS)
-
Digging into MCLA-145 Monotherapy and Combination with Pembrolizumab in solid tumors
Ticker: MRUS
Execute By: Jul 31, 2024
Upcoming & Overdue Catalysts (MRUS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (MRUS)
Strategic Initiatives (MRUS)
-
Incyte (INCY) and Merus N.V (MRUS) Reach Collaboration Agreement to Discover and Develop Bispecific Antibodies
Tickers: INCY, MRUS
Announcement Date: Dec 21, 2016
